Neuralstem, Inc. (NYSEMKT:CUR) Reports Positive Data From Stem Cell Grafts In Lab Animals


Dallas, Texas 04/16/2014 (FINANCIALSTRENDS) –  Neuralstem, Inc. (NYSEMKT:CUR) which is a Rockville based development stage drug maker saw its share price drop by a substantive 5.8 percent during trading on 15th April. The dip occurred on a day when the broader health care index posted healthy 0.65 percent gains at the markets. The selloff in the stock has gathered momentum this month, as the stock has posted 18.7 percent losses since the beginning of this month and has practically reversed all the gains that it had accumulated when the firm had reported positive data from its lab tests on stem cell transplants on 28th March.

The positive data from the study showed that the stem cells that were transplanted surgically into the brains of lab rats which had suffered stroke had resulted in the test subjects displaying improved “post stroke symptoms”. The result highlights and the modalities of these lab tests was shared by Neuralstem, Inc. (NYSEMKT: CUR) in medical journal PLOS ONE and has sought peer review of the findings.

The tests involved rats which had been suffering from induced ischemic-stroke being transplanted with “Neuralstem’s NSI-566 stem cells” in their brains.  After healing, the rats were known to demonstrate appreciable improvements in their body functions. The tests also indicated that the surgically implanted grafts had in due course morphed into neurons as desired under this evaluation process.

Expressing his satisfaction at the positive outcome of these lab tests Neuralstem, Inc. (NYSEMKT:CUR) Chairman of the Board and Chief  Scientific  Officer Karl Johe, Ph.D has been quoted to have said that , “We believe there are many indications we will address with transplantation of cells directly into the brain. We are pleased to see the peer review publication of this important proof of principle data in stroke. This compelling data played an important role in our initiating the stroke trial in China. We wish to thank Dr. Borlongan, and his entire team at the USF Center of Excellence for Aging and Brain Repair, for their efforts in conducting this ground-breaking study.”